Business Context and Reporting Period
This Form 8-K filing by Biorestorative Therapies, Inc. covers events occurring between August 15, 2018, and August 31, 2018. The report details unregistered sales of equity securities and debt-to-equity conversions executed during late August 2018.
Key Financial Metrics and Transactions
- Debt Issuance: The Company issued convertible promissory notes with an aggregate principal amount of $975,000.
- Debt Conversion: The Company issued 385,744 shares of common stock to settle outstanding indebtedness totaling $433,507 (including accrued interest).
- Equity Issuance for Services: The Company issued 35,000 shares of common stock to a consultant for services rendered.
- Equity Issuance for Debt: In connection with one note issuance, 8,333 shares of common stock were issued to a lender.
- Liquidity and Margins: The filing text does not provide specific values for revenue, profit, cash flow, operating margins, or overall liquidity positions.
Material Changes
The primary material change reported is the reduction of outstanding indebtedness by $433,507 through the issuance of equity, alongside the addition of $975,000 in new convertible debt. These transactions alter the Company's capital structure and increase the number of outstanding shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of unregistered securities. The transactions were executed under exemptions from registration (Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933), relying on the status of investors as accredited investors and the absence of general solicitation.
Investor Verification Checklist
- Verify the specific conversion terms and potential dilution impact of the $975,000 in convertible notes, noting the varying conversion prices (ranging from 58% to 65% of fair value or fixed prices).
- Confirm the total number of shares outstanding post-transaction to assess dilution from the 385,744 shares issued for debt and 35,000 shares for services.
- Review the Company's most recent 10-Q or 10-K filings to understand the context of the $433,507 debt settlement and current cash runway.
- Validate the "fair value" of the common stock used in conversion calculations, as this metric significantly influences the final share count.